Pharmafile Logo

Pfizer

- PMLiVE

Pfizer to receive up to $1.5bn in funding from Blackstone Life Sciences

The funding will be for a GLP-1 receptor agonist clinical programme for weight loss

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

Gilead opens new research centre bringing together oncology, inflammation and research data science teams

The centre in California supports the company’s $32bn US investment

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

- PMLiVE

Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

- PMLiVE

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

Fan image of Site Report

New Cuttsy+Cuttsy research shows why site support matters more than ever

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Cuttsy + Cuttsy

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Lack of education causes patients to stop vital treatments, survey finds

Over three quarters of healthcare professionals call for co-created patient materials to drive engagement and trust, ultimately helping more patients benefit from prescribed treatments. Nearly 80% of healthcare professionals identify...

Healthinote (by Cognitant)

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links